Literature DB >> 7901407

The effect of clozapine on preexisting tardive dyskinesia.

K Littrell1, A M Magill.   

Abstract

Since the 1950s, the main treatment for schizophrenia has been the use of neuroleptic therapy. However, these medications may produce tardive dyskinesia in those patients who require prolonged neuroleptic treatment. With the advent of clozapine, patients with preexisting tardive dyskinesia began therapy and their symptoms did not worsen--and, in many cases, their symptoms improved dramatically. In this study, the mean Abnormal Involuntary Movement Scale (AIMS) scores from baseline to 6 months are compared for 12 patients in a private partial hospitalization program for schizophrenia. The findings reveal a drastic decrease in AIMS scores after 1 month of clozapine therapy and a steady decrease in scores throughout the 6 months of analysis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7901407     DOI: 10.3928/0279-3695-19930901-07

Source DB:  PubMed          Journal:  J Psychosoc Nurs Ment Health Serv        ISSN: 0279-3695            Impact factor:   1.098


  8 in total

Review 1.  Movement disorders: neurodevelopment and neurobehavioural expression.

Authors:  T Archer; R J Beninger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-06       Impact factor: 3.575

Review 2.  Extrapyramidal symptoms with atypical antipsychotics : incidence, prevention and management.

Authors:  Joseph M Pierre
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Effects of newer antipsychotics on extrapyramidal function.

Authors:  Daniel Tarsy; Ross J Baldessarini; Frank I Tarazi
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Tardive Dyskinesia: Spotlight on Current Approaches to Treatment.

Authors:  Sarah M Debrey; David R Goldsmith
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-01-25

5.  Relapse of tardive dyskinesia due to reduction in clozapine dose.

Authors:  Meena Shrivastava; Bhupendra Solanke; Ganesh Dakhale; Abhishek Somani; Pravir Waradkar
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

6.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

Review 7.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06

Review 8.  New and emerging treatments for symptomatic tardive dyskinesia.

Authors:  Abdul Qayyum Rana; Zishan M Chaudry; Pierre J Blanchet
Journal:  Drug Des Devel Ther       Date:  2013-11-06       Impact factor: 4.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.